Cytiva Opening a New CGT Switzerland Facility
Among functions, 80,000 square-foot space will house a 'Center of Excellence'
Cytiva, a life sciences company that works to advance and accelerate the development and manufacture of therapeutics, will be opening a near 80,000 square-foot manufacturing facility in Grens, Switzerland on May 31, 2022. The site will manufacture single-use kits for the Sepax and Sefia cell processing systems, along with consumables for Xuri cell expansion systems. It will also serve as a “Center of Excellence” for Cytiva’s cell and gene therapy (CGT) business and will be a base for European customer training programs.
“Cell and gene therapies have the potential to change the global healthcare landscape,” says Catarina Flyborg, vice president, cell and gene therapy. “Our new facility in Grens will enable us to meet global demand for our products, while working with our customers to meet their immediate training and development needs. This facility brings us another step closer to our vision where access to life-changing therapies transforms human health.”
The existing site in Eysins, Switzerland will continue operations through 2023, while full production transfers to the new site in Grens.
